-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4347 Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, adult, Clinical Research, patient-reported outcomes, real-world evidence, Human
Monday, December 12, 2022, 6:00 PM-8:00 PM

Yannick LE Bris, PhD, PharmD1,2*, Jean Galtier3*, Dina Naguib, MD4*, Mathieu Wemeau, MD5,6*, Jean Claude Chomel, MD7*, Laurence Legros, MD, PhD8*, Yan Beauverd, MD9*, Lise Willems, MD10*, Guillaume Denis, MD11*, Françoise Boyer perrard12*, Damien Luque-Paz, PharmD, PhD13*, Kamel Laribi, MD14*, Mélanie Mercier, MD15*, Pascale Cony-Makhoul, MD16*, Olivier Herault, MD17, Lydia Roy, MD18*, Pierre Sujobert, MD, PhD19*, Lenaig Le Clech, MD20*, Sylvie Tondeur, PharmD PhD21*, Gaelle Laboure, MD22*, Jerome Rey, MD23*, Guillou Sophie, MD24*, Cedric Pastoret, MD, PhD25*, Pascaline Etancelin, MD26*, Suzanne Tavitian, MD27*, Charles Bescond, MD28*, Francois Girodon, MD, PhD 29, Shanti Amé, MD30*, Viviane Dubruille, MD31*, Eric Lippert, MD, PhD32*, Chloe James, MD, PhD33*, Barbara Burroni, MD34*, Marc Fouassier, MD35*, Marie C Béné, PharmSciD, PhD36* and Jean Christophe Ianotto, MD, PhD37*

1Hematology Biology, CHU Nantes, Nantes, France
2CRCINA, INSERM, CNRS, Angers University and Nantes University, Nantes, France
3CHU Bordeaux, Service d'hématologie clinique et thérapie cellulaire, PESSAC, FRA
4Laboratoire d'hématologie, CHU de Caen Normandie, Caen, Ca, France
5Hématologie Clinique, Centre Hospitalier de Roubaix, Roubaix, France
6CHRU Lille, Paris, FRA
7CHU De Poitiers, Poitiers, FRA
8Hematology department, Hôpital Paul Brousse, Villejuif, France
9Geneva University Hospitals, Geneva, Switzerland
10Department of Hematology, APHP, Hôpital Cochin, Paris, France
11Department of Internal Medicine and Hematology, Rochefort Hospital, Rochefort, France
12Service des maladies du sang, Centre Hospitalier Universitaire d’Angers, Angers, France
13Hematology biology, CHU Angers, Angers, France
14Hématologie clinique, CH Le Mans, Le Mans, France
15Clinical Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France
16Service d'Hématologie, Centre Hospitalier Annecy-Genevois, Pringy, France
17Service d'Hématologie Biologique, Centre Hospitalier Universitaire, Tours, France
18Hematology department, Hopital Henri Mondor, Creteil, France
19Laboratory of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
20Hematology clinic, Centre Hospitalier de Quimper, Quimper, France
21Laboratoire de Génétique des hémopathies, CHU Grenoble Alpes, Grenoble, France
22Centre Hospitalier de Libourne, Libourne, France
23Onco-Hematology Department, Paoli-Calmette Cancer Institute, Marseille, France
24Hematology biology, CHU Reims, Reims, France
25INSERM U1236 /Hematology Laboratory, University Hospital of Rennes, RENNES, FRA
26Centre Henri Becquerel, Rouen, FRA
27Service d'Hématologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
28CHU De Nantes, Nantes, FRA
29Laboratorie D'Hematologie CHU Dijon, Dijon, France
30Hematology department, Hopital Civil , CHU Strasbourg, Strasbourg, France
31Hematology Department, Nantes University Hospital, Nantes, France
32France Intergroupe des Néoplasies Myéloprolifratives, FIM collaborative group, Paris, France
33UMR Inserm U1034, 33600, FRA
34Pathology Department, Hopital Cochin, Paris, France
35CHRU Hotel Dieu, Nantes cedex, FRA
36Biology Department, Nantes University Hospital, Nantes, France
37Department of Hematology, CHU de Brest, Brest, FRA


Thrombosis is the main cause of morbidity in myeloproliferative neoplasms (MPN) and can be the mode of revelation of these malignant diseases. Most of them are characterized by specific driver mutations such as JAK2 V617F, CALR or MPL. An idiopathic or atypical thrombotic event justifies looking for MPN by searching these MPN-related mutations, even in the absence of myeloproliferative features on the complete blood count (CBC). This is especially crucial in case of splanchnic and cerebral thromboses, but not only. In this context the diagnosis of MPN and the choice of treatment are made difficult by the absence of increased blood counts.


- To constitute an observational cohort of patients (pts) presenting an arterial or venous thrombotic event leading to a suspicion of MPN without signs of myeloproliferation in CBC.

- To study the characteristics of pts at diagnosis, the rate of recurrence of thrombosis and the rate of hematological progression.

Patients and method

Inclusion criteria were as follows: i)-diagnosis of an arterial or deep venous thrombotic event, ii)-CBC not suggestive of polycythemia vera (PV), essential thrombocythemia (ET) or myelofibrosis (MF) (CBC below WHO 2016 thresholds) but iii)-detection of a molecular abnormality (JAK2, CALR or MPL driver mutations) and/or an abnormality on bone marrow trephine in favor of MPN and/or spontaneous progenitor growth. Data were collected retrospectively and prospectively. The study is registered on ClinicalTrial.gov (NCT04539678).


Between 05/2019 and 06/2022, the participation of 31 centers in France and Switzerland allowed the collection of data from 216 pts. The analysis is presented for 208 pts after exclusion of incomplete non-evaluable cases (n=5) or those not meeting inclusion criteria (n=3). The M/F sex ratio was 1.3 with a median age of 55 years (22-91) at the date of molecular testing. Inaugural thrombosis was venous (80%) or arterial (20%) and involved either splanchnic (50%), cerebral (24%), other locations (23%) or multiple territories (3%). Median CBC values were hemoglobin 14 g/dL, hematocrit 43%, platelets 298x109/L and leukocytes 7,1 x109/L. Pts had either a driver mutation of JAK2 V617F (n=201), CALR (n=2) or MPL (n=2), or none of these but spontaneous progenitor growth (n=3). According to WHO criteria, the diagnoses retained were MPN in 91 (44%) cases (including 26 PV, 4 MF and 61 unclassifiable MPN), while 38 pts (18%) lacked MPN criteria and 79 (38%) were not assessable (no trephine).

A clinical follow-up of at least 3 months was available in 197 pts, with a median of 61 months (range 3 months - 36 years). Recurrent thrombosis occurred for 42 pts (21%, respectively 24% of initially arterial and 19% of initially venous). Recurrence was splanchnic for 13 pts (31%). The median delay of recurrence was 37 months (12 days - 18 years) after the thrombotic event that led to a suspicion of MPN. Recurrence occurred more often in pts with initially non-splanchnic thrombosis (30% vs. 13% p=0.004). Thrombosis recurrences were not significantly different between pts classified as MPN and those without MPN criteria (18% vs. 30% p=0.1). Hematological progression was observed for 27 pts with a median delay of 31 months (1 - 105) since thrombosis. According to WHO MPN criteria, they were 9 PV, 14 TE and 4 MF. Pts with thrombotic recurrence more frequently presented hematological progression or died (31 month progression-free survival [PFS] 85% vs 94% p=0.008). PFS was significantly reduced in cases of initially non-splanchnic thrombosis (86% vs 97% at 31 months p<0.0001). An explanation could be that pts with splanchnic thrombosis were more frequently treated with cytoreductive agents (CRA) (71% vs 41% p=0.03). Analysis of the effect of antithrombotic therapy is ongoing.


Thrombosis cases with a non-proliferative CBC but with MPN driver mutations leading to MPN suspicion constitute a heterogeneous group of pts, with many cases of non-splanchnic involvement. The latter pts show more frequent thrombotic recurrences and hematological progression than pts with splanchnic involvement. The role of cytoreduction and antithrombotic therapies needs to be explored in this context.

Disclosures: Willems: Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Remuneration; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Remuneration; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: nature advantage (congress inscription) or convention; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: nature advantage (congress inscription) or convention. Boyer perrard: Novartis: Honoraria. Laribi: AbbVie, AstraZeneca, Beigene, Iqone, Janssen, Novartis, Takeda: Honoraria. Cony-Makhoul: Pfizer, Novartis Pharma, Incyte: Consultancy, Other: Support for travels; Research grants to CH Annecy Genevois for observational and clinical studies, Speakers Bureau. Sujobert: Astrazeneca: Research Funding; Janssen: Research Funding; Gilead/Kyte: Consultancy; Astellas: Consultancy; Daichi Sankyi: Consultancy. Tavitian: Pfizer: Other: ASH 2021 (invitation); Novartis: Other: Symposium; Servier: Honoraria.

*signifies non-member of ASH